261 related articles for article (PubMed ID: 18644993)
1. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.
Guan H; Zhou Z; Gallick GE; Jia SF; Morales J; Sood AK; Corey SJ; Kleinerman ES
Mol Cancer Ther; 2008 Jul; 7(7):1807-16. PubMed ID: 18644993
[TBL] [Abstract][Full Text] [Related]
2. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.
Winter GE; Rix U; Lissat A; Stukalov A; Müllner MK; Bennett KL; Colinge J; Nijman SM; Kubicek S; Kovar H; Kontny U; Superti-Furga G
Mol Cancer Ther; 2011 Oct; 10(10):1846-56. PubMed ID: 21768330
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
4. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA‑34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1.
Lu Q; Lu M; Li D; Zhang S
Mol Med Rep; 2018 Oct; 18(4):3577-3588. PubMed ID: 30106161
[TBL] [Abstract][Full Text] [Related]
6. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
Kinsey M; Smith R; Lessnick SL
Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
8. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
[TBL] [Abstract][Full Text] [Related]
9. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells.
Girnita L; Girnita A; Wang M; Meis-Kindblom JM; Kindblom LG; Larsson O
Oncogene; 2000 Aug; 19(37):4298-301. PubMed ID: 10980604
[TBL] [Abstract][Full Text] [Related]
10. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro.
Chansky HA; Barahmand-Pour F; Mei Q; Kahn-Farooqi W; Zielinska-Kwiatkowska A; Blackburn M; Chansky K; Conrad EU; Bruckner JD; Greenlee TK; Yang L
J Orthop Res; 2004 Jul; 22(4):910-7. PubMed ID: 15183454
[TBL] [Abstract][Full Text] [Related]
11. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
12. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES
Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647
[TBL] [Abstract][Full Text] [Related]
13. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
15. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo.
Guan H; Jia SF; Zhou Z; Stewart J; Kleinerman ES
Clin Cancer Res; 2005 Mar; 11(5):2008-17. PubMed ID: 15756027
[TBL] [Abstract][Full Text] [Related]
16. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
[TBL] [Abstract][Full Text] [Related]
18. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit.
Landuzzi L; De Giovanni C; Nicoletti G; Rossi I; Ricci C; Astolfi A; Scopece L; Scotlandi K; Serra M; Bagnara GP; Nanni P; Lollini PL
Am J Pathol; 2000 Dec; 157(6):2123-31. PubMed ID: 11106584
[TBL] [Abstract][Full Text] [Related]
19. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas.
Yu L; Su B; Hollomon M; Deng Y; Facchinetti V; Kleinerman ES
Cancer Res; 2010 Feb; 70(4):1334-43. PubMed ID: 20124484
[TBL] [Abstract][Full Text] [Related]
20. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
